The Galien Foundation announced the 2017 11th Annual Prix Galien USA Award Nominees. Counted among the global health innovation industry's most prized honors, the Prix Galien Award recognizes outstanding biomedical and technology product achievement that improves the human condition.
To qualify, each candidate must be U.S. Food and Drug Administration (FDA) approved for market within the last five years and demonstrate tremendous potential to impact human health. Sales data are not considered by the nominating committee in their award nominee selection; only science and health impact.
"The 2017 nominees are working each day to ensure a healthier future for the next generation," said Dr. P. Roy Vagelos, chairman, Prix Galien USA Awards Committee, and prior recipient of the Pro Bono Humanum Award. "The selection committee appreciates the unwavering devotion by the teams of researchers, scientists and innovators that have dedicated their lives to such a worthy cause, and we are honored to recognize their achievements."
The Prix Galien USA 2017 nominees include in-market products evaluated in the following categories: "Best Biotechnology Product" – 15 nominees; "Best Pharmaceutical Agent" – 34 nominees, and "Best Medical Technology" – 11 nominees.
"As the realm of scientific discovery and medical innovation shuttles forward, we were thrilled to see so many high-caliber submissions this year," said Bruno Cohen, chairman of the Galien Foundation. "Our Foundation is continually impressed by the achievement of the Prix Galien candidates each year, but 2017 has become a benchmark for future years."
The Prix Galien USA Committee is comprised of thirteen renowned leaders from the biomedical industry and academia, including four Nobel Laureates, responsible for evaluating nominees. Winners will be announced during the Prix Galien USA Awards Ceremony on October 26, 2017, at the American Museum of Natural History in New York City.